Noopept is a peptide-derived nootropic that is closely related to the racetam family. It has higher bioavailability than the racetams. Although, it is not technically a racetam, it carries a similar method of action to the drug class. Noopept is a patented drug with medical approval in several countries as a general nootropic. There is currently no registered medical use in the USA and other countries.

Noopept is famously quoted as being “1000 times stronger than Piracetam”. This is a true statement in terms of potency because Noopept gets metabolized much more efficiently than the racetam family. This means a much lower dosage is needed to get desired results from the drug. This requires one to be much more careful with their dosing practices.

Noopept’s method of action is similar to the other racetams. Noopept works on the AMPA and NDMA receptor sites and their pathways of function. It also has an affinity with the Acetylcholine system and the ACh receptor sites. Both of these factors contribute to Noopept’s array of nootropic benefits.

Like Aniracetam, Noopept seems to stimulate an anxiolytic response in animal and human models. This is not a guaranteed result and seems to vary widely between subjects. Like with Aniracetam, Noopept seems stimulate Dopamine receptor sites (D2 and D3) as well as the ACh nicotinic receptor sites. Noopept also seems to stimulate certain Serotonin receptors and this may also lead to mood boosting qualities.

Noopept is being investigated as a possible treatment for Alzheimer’s. It is believed by some that it may work beyond the areas of increasing cognition and memory. In lab rats NGF (nerve-growth factor) was increased after administration. This reflects some promise in repairing damaged cells and receptor sites that are commonly seem in Alzheimer’s patients. There is no proof this may be repeated in human models and it is investigated in the pharmacological industry.